Authors
Faisal Bin Ashraf, Karen Paco, Sanaz Zebardast, Zihao Zhang, Ryan Mooney, Christian J Dávila Ojeda, Mariana Paco Mendivil, Rashid M Alam, Eva Chen, Iraneus Ogu, Jordan A Lay, Tristan Y Yang, Fernando L Barroso da Silva, Malkiat Johal, Ilya Tolstorukov, Matthew H Sazinsky, Animesh Ray, Stefano Lonardi
Published in
PLoS computational biology. Volume 22. Issue 11. Pages e1014924. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
The capacity of an antibody to recognize and bind an antigen with high specificity and strength (i.e., its binding affinity) is a key determinant in the design and optimization of neutralizing antibodies against pathogenic targets. Here we introduce Ab-Affinity, a fine-tuned protein language model (PLM) that predicts the binding affinity of an antibody against a target peptide within the SARS-CoV-2 spike protein. Cross-validation results shows that that Ab-Affinity outperforms other PLM-based affinity predictors when evaluated on a held-out validation and independent test sets. When integrated with a genetic algorithm and simulated annealing for sequence diversification and fitness optimization, Ab-Affinity enables the generation of candidate antibodies exhibiting over 100-fold improvement in predicted binding affinity relative to its parental (natural) antibody. More broadly, antibodies designed with Ab-Affinity attain higher predicted binding affinities than those produced by alternative mutational strategies, yielding synthetic antibodies with favorable predicted biophysical characteristics. Molecular docking and molecular dynamics simulations for the strongest synthetic candidates indicate enhanced interactions and increased stability with the target peptide epitope within the spike protein. Experimental validation in vitro for a top-ranked candidate reveals an apparent increase in binding relative to its parental antibody. All model weights, source code, and analysis pipelines are publicly released to allow full reproducibility.
PMID:
43013634
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 39
- Comments 0